Contineum Therapeutics Q3 net loss widens to $18.7 million from $12.8 million
Contineum Therapeutics reported third-quarter 2026 results on November 3, 2026. The net loss widened to $18.7 million from $12.8 million a year earlier, driven by higher research and development and general and administrative expenses. The company reported $244.5 million in cash, cash equivalents and marketable securities as of September 30, 2026, and said this is sufficient to fund planned operations through mid-2029.
Key points
- Net loss for the three months ended September 30, 2026 was $18.7 million, compared with $12.8 million in the third quarter of 2025.
- Research and development expenses were $16.0 million, up 45 percent from a year earlier, mainly due to the PIPE-791 IPF program and employee-related costs.
- General and administrative expenses were $5.0 million, up 26 percent, mainly due to higher stock-based compensation and employee-related costs.
- Cash, cash equivalents and marketable securities were $244.5 million at September 30, 2026.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.